Head-To-Head Comparison: Aurinia Pharmaceuticals (AUPH) & The Competition

Aurinia Pharmaceuticals (NASDAQ:AUPH) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Aurinia Pharmaceuticals to related businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, earnings, valuation and dividends.

Earnings & Valuation

This table compares Aurinia Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05 million	$287.20 million	7.28
Aurinia Pharmaceuticals Competitors	$735.22 million	$13.62 million	-10.06

Aurinia Pharmaceuticals’ peers have higher revenue, but lower earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Aurinia Pharmaceuticals has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals’ peers have a beta of 1.10, suggesting that their average share price is 10% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Aurinia Pharmaceuticals and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	3	3	1	2.71
Aurinia Pharmaceuticals Competitors	9782	15052	45294	1571	2.54

Aurinia Pharmaceuticals currently has a consensus target price of $18.25, indicating a potential upside of 9.41%. As a group, “Biotechnology” companies have a potential upside of 97.80%. Given Aurinia Pharmaceuticals’ peers higher possible upside, analysts clearly believe Aurinia Pharmaceuticals has less favorable growth aspects than its peers.

Insider and Institutional Ownership

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Aurinia Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Aurinia Pharmaceuticals Competitors	-9,054.47%	-198.89%	-30.64%

Summary

Aurinia Pharmaceuticals beats its peers on 8 of the 13 factors compared.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.